UK markets open in 1 hour 32 minutes
NIKKEI 225
26,781.44 -220.08 (-0.82%) HANG SENG
20,149.66 -320.40 (-1.57%) CRUDE OIL
109.57 -0.72 (-0.65%) GOLD FUTURES
1,854.10 +6.30 (+0.34%) DOW
31,880.24 +618.34 (+1.98%) BTC-GBP
23,377.15 -734.96 (-3.05%)
Abeona Therapeutics Inc. (0H7R.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 04:51PM BST
| Previous close | 0.17 |
| Open | 0.22 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.18 - 0.22 |
| 52-week range | 0.18 - 0.22 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 447.692M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
- Zacks
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.
- Zacks
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.
© 2022 Yahoo. All rights reserved.
